|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0018338,
umls-concept:C0022646,
umls-concept:C0126174,
umls-concept:C0162367,
umls-concept:C0216784,
umls-concept:C0390423,
umls-concept:C0597357,
umls-concept:C1332036,
umls-concept:C1412113,
umls-concept:C1705241,
umls-concept:C1705242,
umls-concept:C1705845,
umls-concept:C1948023
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-5-22
|
|
pubmed:abstractText |
Angiotensin II-receptor blockers are an established class of antihypertensive agents, but the differences between individual members of the class are largely unknown. The present study employed an animal model to demonstrate angiotensin II-receptor blocker-specific effects and to quantify these differences by comparing two common agents, losartan and valsartan.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic GMP,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/PD 123319,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Angiotensin,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Valine,
http://linkedlifedata.com/resource/pubmed/chemical/valsartan
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0263-6352
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1157-63
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12023686-Administration, Oral,
pubmed-meshheading:12023686-Angiotensin II,
pubmed-meshheading:12023686-Angiotensin Receptor Antagonists,
pubmed-meshheading:12023686-Animals,
pubmed-meshheading:12023686-Blood Pressure,
pubmed-meshheading:12023686-Cyclic GMP,
pubmed-meshheading:12023686-Extracellular Space,
pubmed-meshheading:12023686-Female,
pubmed-meshheading:12023686-Imidazoles,
pubmed-meshheading:12023686-Injections, Intravenous,
pubmed-meshheading:12023686-Kidney,
pubmed-meshheading:12023686-Losartan,
pubmed-meshheading:12023686-Pyridines,
pubmed-meshheading:12023686-Rats,
pubmed-meshheading:12023686-Rats, Sprague-Dawley,
pubmed-meshheading:12023686-Receptor, Angiotensin, Type 1,
pubmed-meshheading:12023686-Receptor, Angiotensin, Type 2,
pubmed-meshheading:12023686-Receptors, Angiotensin,
pubmed-meshheading:12023686-Tetrazoles,
pubmed-meshheading:12023686-Valine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
|
|
pubmed:affiliation |
Department of Internal Medicine, University of Virginia Health System, Charlottesville, Virginia 22908, USA. hms7a@virginia.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.
|
